Meeting NewsVideo

VIDEO: Aerie announces Rocklatan launch

SAN DIEGO At the Ophthalmology Innovation Summit, Vicente J. Anido Jr., PhD, chairman and CEO of Aerie Pharmaceuticals, discusses the market launch of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in the U.S., as well as the company’s pipeline and progress in international markets.

SAN DIEGO At the Ophthalmology Innovation Summit, Vicente J. Anido Jr., PhD, chairman and CEO of Aerie Pharmaceuticals, discusses the market launch of Rocklatan (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in the U.S., as well as the company’s pipeline and progress in international markets.

    See more from Ophthalmology Innovation Summit